RESUMO

PURPOSE: Total hip arthroplasty (THA) has demonstrated excellent results in elderly patients, however, the indications, outcomes, and long-term results in adolescent patients are less understood. This study aims to assess the outcomes of THA in patients under 21, providing insights for clinical decision-making in this exceptional population. METHODS: A systematic review in PubMed, Ovid MEDLINE, and Embase database was performed. We included studies reporting clinical, radiological, and functional outcomes of THA in patients younger than 21 years, for any cause, with a with a minimum follow-up of one year. The ten year survivorship estimate was pooled using a meta-analysis methodology and each study was weighted according to its standard error, calculated from published confidence intervals. RESULTS: We included 25 studies involving 1166 hips. Median age was 17 years old, 60% were females, and the average follow-up was 8.1 years. Juvenile inflammatory arthritis was the main indication for total hip arthroplasty (THA). The all-cause revision rate was 14.4% and aseptic loosening was the most common cause. Only eight studies reported ten year survival rates and form the pooled analysis an 84.91% survival rate (95% CI 70.56 - 99.27) was obtained. An average score of 88.08 in the Harris Hip Score (HHS) was observed. We found a 3.43% complication rate. CONCLUSIONS: Hip arthroplasty is an acceptable option for adolescents with end-stage arthritis. However, the altered hip anatomy, the elevated revision rate, and the long-term implant survival must be considered before performing a THA in adolescent patients.

Assuntos

RESUMO

INTRODUCTION: Posterolateral approach (PA) has been historically associated with an increased risk of dislocation after primary total hip arthroplasty (THA), especially when compared with the direct anterior approach (DAA). However, current evidence is inconsistent regarding the risk of dislocation with either approach. The purpose of this study is to determine whether surgical approach influences joint stability. METHODS: A systematic search in PubMed, MEDLINE, and Embase databases was performed. Randomized controlled trials (RCTs) and non-RCTs comparing DAA with PA in primary THA were included. Pooled effect measure of risk differences, relative risk and mean differences for postoperative dislocation, acetabular implant positioning, and leg length discrepancy were calculated. RESULTS: Twenty-five studies (5 RCTs and 20 non-RCTs) of 7,172 THAs were assessed. There were no significant differences in dislocation rates between approaches (risk difference = -0.00, 95% confidence interval: -0.01 to 0.00; P = 0.92; I2 = 0%). Results were similar in the subgroup analysis of RCTs (P = 0.98), posterior soft-tissue repair (P = 0.50), and learning curve (P = 0.77). The acetabular implant was better positioned within the safe zone in the DAA group (relative risk = 1.17; 95% confidence interval: 1.03 to 1.33; P = 0.01), but no significant differences were found in cup inclination (P = 0.8), anteversion (P = 0.10), and leg length discrepancy (P = 0.54). CONCLUSION: Dislocation rates after THA are not different between DAA and PA. Furthermore, no differences in the rate of dislocation were associated with cup positioning or surgical factors related with hip instability. Therefore, the surgical approach has little influence in prosthesis instability after primary THA. LEVEL OF EVIDENCE: Level III.

Assuntos

RESUMO

BACKGROUND: In primary total hip arthroplasty (THA), evidence supports the use of tranexamic acid (TXA) as an effective strategy for reducing blood loss, but scant evidence supports its use in revision THA. QUESTIONS/PURPOSES: We aimed to evaluate whether the use of topical TXA in revision THA is associated with less blood loss and lower transfusion rates and to assess its safety, specifically as it relates to thromboembolic complications. METHODS: In this retrospective comparative study, two groups who underwent revision THA between 2005 and 2017 were defined: 98 patients who received 3 g of topical TXA (study group) and 475 patients who did not receive TXA (control group). Subjects were divided into subgroups according to the type of revision. Hemoglobin and hematocrit levels, blood loss, and transfusions were recorded. The follow-up period was 6 weeks. RESULTS: Median estimated blood loss, hidden blood loss, hemoglobin drop, and transfusion rates were significantly lower in the study group. The rates of post-operative thromboembolism were similar in the two groups. According to subgroup analysis, patients with revision of the femoral component, both components, and staged exchange revisions showed significantly lower rates of transfusion. CONCLUSION: Topical TXA administration during revision THA effectively reduced direct and indirect blood loss, including hidden losses, without increasing the rates of thromboembolic events. This effect appeared to be enhanced when the femoral component was revised.

Assuntos

RESUMO

BACKGROUND: The use of tranexamic acid (TXA) has been proved to be effective in reducing blood loss and transfusion requirements after primary total knee arthroplasty (TKA). However, the evidence for its use in revision surgery is scant. We assessed the safety and efficacy of topical TXA in revision TKA. METHODS: We retrospectively compared 76 revision TKA patients who received topical TXA (3 g before tourniquet deflation) "study group" with a historic control group of 205 revision TKA patients in which TXA was not used. Each group was further stratified into subgroups according to the type of revision. All patients were followed for a minimum of 6 weeks. Blood loss, transfusion requirements, changes in hemoglobin-hematocrit levels, Knee Society Score, and complications were recorded. RESULTS: The mean estimated blood loss, hemoglobin drop, and transfusion rate were significantly lower in the study group than in the control group (P = .008, P < .001, P < .001, respectively). Hidden blood loss was similar between the 2 groups (P = .12). Six weeks postoperatively, the improvement in the knee-specific Knee Society Score was significantly higher in the study group than in the control group (P < .001). No significant differences were found in thromboembolic complications between the 2 groups (P = .92). In the subgroup analysis, when both components (femur and tibia) were revised, the relative risk of transfusion was significantly lower with the use of TXA (relative risk 0.227, confidence interval 0.0593-0.860, P = .004). CONCLUSION: Topical TXA in revision TKA is safe and effective in reducing blood loss and transfusions. This effect is enhanced when both components are revised. Additionally, the use of TXA may improve early outcomes.

Assuntos

RESUMO

INTRODUCTION: Diagnosing periprosthetic joint infection (PJI) before revision hip arthroplasty is critical to ensure effective treatment of patients undergoing surgery for reasons other than infection. The main objective of our study is to determine whether the erythrocyte sedimentation rate (ESR) and the serum C-reactive protein (CRP) level are sufficient to use for testing to rule out infection in patients undergoing revision hip surgery. METHODS: We performed a systematic review of the literature in the MEDLINE, Ovid, and Embase databases. We included studies in which the investigators used the ESR (>30 mm/h) and serum CRP level (>10 mg/L) for the diagnosis of PJI of the hip. We obtained meta-estimates of sensitivity, specificity, positive likelihood ratio (LR+), and negative likelihood ratio (LR-). RESULTS: From 511 articles, we analyzed 12 studies in which the investigators reported data on 2,736 patients. Sensitivity and specificity for the ESR were 0.860 (95% confidence interval [CI], 0.825 to 0.890) and 0.723 (95% CI, 0.704 to 0.742), respectively, and for the CRP level were 0.869 (95% CI, 0.835 to 0.899) and 0.786 (95% CI, 0.769 to 0.803), respectively. For the ESR, LR+ was 3.42 (95% CI, 2.55 to 4.59) and LR- was 0.22 (95% CI, 0.12 to 0.41). For the CRP level, LR+ was 4.18 (95% CI, 3.42 to 5.11) and LR- was 0.20 (95% CI, 0.12 to 0.32). DISCUSSION: With a low pretest probability of PJI, a negative test result for either the ESR or CRP level is enough to rule out infection before revision hip arthroplasty. LEVEL OF EVIDENCE: III.

Assuntos

RESUMO

Introducción: la enfermedad renal crónica se asocia con alteraciones metabólicas severas que llevan a hiperparatiroidismo secundario (HPTS). El trasplante de riñón corrige las alteraciones fisiopatológicas que lo originan. Objetivo: describir cambios al año y a los tres años de seguimiento en los niveles séricos de hormona paratiroidea intacta (PTHi) y perfil fosfocálcico en pacientes llevados a trasplante renal con diagnóstico previo de HPTS. Metodología: se realizó un análisis descriptivo de todos los pacientes trasplantados entre 2005 y 2012, evaluando niveles de PTHi y perfil fosfocálcico antes del trasplante, al año y a los tres años de seguimiento. Resultados: en el pretrasplante el promedio de PTHi de los 175 pacientes fue 465.4 pg/dL; en 30.2% de los pacientes se encontraron niveles superiores a nueve veces el valor normal. Al año de seguimiento la tasa de filtración glomerular (TFG) promedio fue 65.4 mL/min/1.73 m². La PTH (114 pacientes), fue en promedio 118.7 pg/dL, con una disminución promedio de 339 pg/dL. Fue mayor la PTH en los que presentaban TFG menor a 40. Al tercer año de seguimiento los hallazgos se mantuvieron en todos los pacientes, con PTHi promedio de 100.4 pg/dL (un descenso de 396 pg/dL). Conclusiones: en este estudio se encontró que el HPTS mejora después del trasplante renal, con una disminución significativa de los niveles de PTHi al primero y tercer años de seguimiento

Introduction: chronic kidney disease is associated with severe metabolic abnormalities that lead to secondary hyperparathyroidism (SHPT). Kidney transplant corrects pathophysiological abnormalities that originate it. Objective: to describe changes at one year and at three years of follow- up of serum levels of intact parathyroid hormone (PTH) and calcium-phosphorus profile in patients undergoing renal transplantation with a previous diagnosis of SHPT. Methodology: a descriptive analysis of all patients transplanted between 2005 and 2012 was performed assessing levels of iPTH and calcium-phosphorus profile before transplantation, and after one year and three years of follow-up. Results: pre-transplant iPTH average of 175 patients was 465.4 pg / dL; in 30.2% of patients levels higher to nine times the normal value were found. At one year follow-up, glomerular filtration rate (GFR) average was 65.4 mL / min / 1.73 m². PTH (114 patients), averaged 118.7 pg / dL, with an average decrease of 339 pg / dL. PTH was greater in those with GFR less than 40. In the third year of follow-up findings were maintained in all patients with iPTH average of 100.4 pg / dL (a decrease of 396 pg / dL).

Assuntos

RESUMO

El síndrome pulmón-rinón ˜ (SPR) se define como la presencia de hemorragiaalveolar y glomerulonefritis rápidamente progresiva. Fue descrito, inicialmente, como síndromeantimembrana basal glomerular, aunque existen otros mecanismos más frecuentesimplicados en la lesión, tales como vasculitis ANCA (anticitoplasma de neutrófilo), lupuseritematoso sistémico, síndrome antifosfolípido, crioglobulinemia y microangiopatía trombótica.Objetivo: Describir la experiencia de nuestro centro en el manejo de pacientes con SPR,analizar las variables demográficas, clínicas y sus desenlaces.Métodos: Se revisaron las bases de datos de la Unidad de Nefrología y la historia clínicaelectrónica SAHI del Hospital Universitario San Ignacio.Resultados: Se identificaron un total de 14 pacientes que presentaron SPR, entre enero de2009 y agosto de 2011, todos, inicialmente, manejados en la unidad de cuidado intensivodel hospital, con un promedio de edad de 44 anos ˜ y 57% de sexo femenino. El diagnósticomás frecuente fue vasculitis ANCA positivo en 8 pacientes, lupus en 4, un caso decrioglobulinemia y uno de microangiopatía trombótica. La mayoría recibió tratamiento concorticosteroides, ciclofosfamida y plasmaféresis. La mortalidad fue de 66%.Conclusiones: Presentamos los resultados de 14 pacientes con SPR en nuestro centro. La causamás frecuente fue vasculitis ANCA. Su presentación suele ser agresiva y el tratamientoincluye uso de esteroides, ciclofosfamida y plasmaféresis...

Pulmonary- renal syndrome (PRS) is defined as the presence of alveolar hemorrhageand rapidly progressive glomerulonephritis. It was initially described as glomerularbasement membrane syndrome, although other more common causes and mechanisms areinvolved such as, anti-neutrophil cytoplasmic antibody-associated vasculitis (ANCA), systemiclupus erythematosus, antiphospholipid syndrome, cryoglobulinemia, and thromboticmicroangiopathy.Objective: To describe the experience in the treatment of patients with PRS in our centerand analyze the demographic, clinical variables, and outcomes.Methods: The databases of the Nephrology Unit and the electronic medical records of thehospital were reviewed, and a total of 14 patients with PRS between January 2009 and August2011 were identified.Results: A total of 14 cases managed in the intensive care unit of the hospital where analyze,of which 57% were woman and the mean age was 44 years. The most frequent diagnosiswas positive ANCA vasculitis in 8 patients, lupus in 4, one case of cryoglobulinemia, andother with thrombotic microangiopathy. Most of them were treated with corticosteroids andcyclophosphamide, with 10 patients also receiving plasmapheresis. The overall mortalitywas 66%.Conclusions: The results of 14 patients with PRS in our center are presented. The mostcommon cause of this was positive ANCA vasculitis. It is an aggressive disease and itstreatment included the use of steroids, cyclophosphamide and plasmapheresis...

Assuntos